Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new drug shield lungs from COVID-19's worst damage?

NCT ID NCT04472728

Terminated Disease control Sponsor: Biophytis Source: ClinicalTrials.gov ↗

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This trial tests whether an experimental drug called BIO101 can prevent severe breathing problems in hospitalized adults with COVID-19 pneumonia. Participants receive either BIO101 or a placebo for 28 days, and researchers track who develops respiratory failure, needs high-flow oxygen, or dies. The goal is to see if activating a protective pathway in the body can reduce the most dangerous complications of the infection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
BIO101 (also called Sarconeos), an experimental drug that activates the Mas receptor to protect the lungs from severe damage
What this could lead to
If successful, BIO101 could become a treatment to prevent respiratory failure and reduce the need for mechanical ventilation in hospitalized COVID-19 patients.
What could go wrong
This is an early-to-mid-stage trial with a modest number of participants, so results may not be conclusive. The drug could also cause side effects or fail to show a clear benefit over placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19 SARS-COV2

Contacts and locations

Locations

  • AZ-Sint Maarten

    Mechelen, 2800, Belgium

  • Abrazo Health

    Phoenix, Arizona, 85015, United States

  • Avenida Dr. Enéas de Carvalho Aguiar, 44 - Centro de Pesquisa Clínica Prof. Dr. Fúlvio Pileggi - Bloco 1 - 1º Andar

    São Paulo, 103.034, Brazil

  • Barnum Medical Research, Inc. 1029 Keyser Ave Suite H

    Natchitoches, Louisiana, 71457, United States

  • Beaumont Health

    Royal Oak, Michigan, 48073, United States

  • CHU CLU Namur (Saint-Elisabeth) Place Louise Godin

    Namur, 15 5000, Belgium

  • CHU Saint-Pierre

    Brussels, Belgium

  • Centre Hospitalier Argenteuil

    Argenteuil, France

  • Centre Hospitalier Départemental de Vendée

    La Roche-sur-Yon, France

  • Centre Hospitalier Rene Dubos

    Cergy-Pontoise, France

  • Centre Hospitalier Universitaire Bordeaux

    Bordeaux, France

  • FDI Clinical Research - San Juan City Hospital

    San Juan, 00927, Puerto Rico

  • Hospital Municipal de Barueri Dr. Francisco Moran

    Barueri, São Paulo, Brazil

  • Hospital Vera Cruz

    Belo Horizonte, Minas Gerais, Brazil

  • Hospital de Base Da Faculdade de Medicina de São José Do Rio Preto

    São José do Rio Preto, São Paulo, Brazil

  • Hospital e Maternidade Celso Pierro - PUCCAMP

    Campinas, São Paulo, Brazil

  • Hôpital Pitié-Salpêtrière, 47 bd de l'Hôpital, 75013 Paris

    Paris, 75013, France

  • Santa Casa de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

  • United Health Services Hospitals

    Johnson City, New York, 13903, United States

  • Unité ambulatoire Service de Pneumologie, Médecine Intensive et Réanimation (SPMIR) 47-83 Boulevard de l'Hôpital

    Paris, Paris Cedex 13, 75651, France

  • University of California, Irvine

    Irvine, California, 92697, United States

  • WellSpan Health

    York, Pennsylvania, 17403, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.